The Company currently conducts its affairs so that its shares can be recommended by IFAs to ordinary retail investors in accordance with the FCA's rules in relation to non-mainstream investment products and intends to continue to do so for the foreseeable future. The Company's shares are excluded from the FCA's restrictions which apply to non-mainstream investment products because they are shares in an investment trust.
Susan served as the Chief Executive of Touchstone Innovations plc (formerly Imperial Innovations plc) from January 2002 to July 2013, where she led funding rounds totalling circa £250m. During her tenure, Touchstone Innovations invested £121m in a portfolio of healthcare, engineering and software businesses linked to major universities.
Previously she was chair of Mercia Asset Management plc and worked at Montech in Australia (science commercialisation), Signet Group plc, Bank of Nova Scotia and Shell Chemicals in a variety of business development and commercial roles. Susan currently serves as a non-executive director of both Benchmark Holdings plc and QinetiQ Group plc and was until recently a senior independent director of Horizon Discovery Group plc, prior to its acquisition by PerkinElmer, Inc. in December 2020. Susan has an MA in Chemistry from Oxford University.
Stephen has extensive asset management and fund experience. He spent the bulk of his career at Mercury Asset Management where he led both investment teams and business units. He has been actively involved with open-end and closed-end funds, in multiple jurisdictions, for over 34 years. He is currently the Chair of the Audit Committee at JPMorgan Japan Investment Trust plc, a Commissioner at the Gambling Commission and a Council Member at the Health & Care Professions Council.
Scott is Chief Executive of Nexeon Limited, an Imperial College spin-out focused on developing silicon anode technology for next generation Li-ion battery technology. During his tenure, he has led the change in the company’s strategy to successfully move from an IP licensing business model to one of material production and supply. Previously, Scott was Executive Vice President at Cambridge Display Technology (CDT), responsible for commercial and IP activities of the company. Prior to CDT, Scott was Global R&D Director for the Electronic Materials Business at Dow Corning, a US headquartered multinational corporation with over US$6bn in annual revenues. Scott holds a PhD in Chemistry and is a Fellow of the Royal Society of Chemistry.
Jane has spent the majority of her career at Ruffer Investment Management, which she co-founded in 1994 and where she worked until 2014. She is currently chair of Odyssean Investment Trust PLC and ICG Enterprise Trust PLC and a senior independent director of Record PLC. Jane is a graduate of the University of Cambridge.
Raymond has strong experience in the investment trust sector and also brings expertise in early stage technology investments. Raymond is the Chairman of Foresight 4 VCT plc, Scottish Building Society and Integrated Environmental Solutions Ltd and he has recently been appointed as Chair of the advisory panel for the North East Fund.
Raymond is an accountant by background, beginning his career at KPMG before pursuing a career in venture capital and private equity, latterly as Managing Director, Alliance Trust Equity Partners. He has experience as a board director and a fund manager with an emphasis on private equity.
Tim is a qualified chartered accountant with a widespread background in corporate finance and investment. He is currently the chairman of Storm Therapeutics Ltd, Karus Therapeutics Ltd and Modulus Oncology Ltd, a director of AstronauTx Ltd and an independent non-executive director of Record plc. Previously, Tim was a member of the governing board of InnovateUK, the UK’s innovation agency, a director of the UK Cell and Gene Therapy Catapult and chairman of the UK BioIndustry Association.